


8 OUT OF 10 PATIENTS ARE COVERED^{1,*}

REPATHA[®] IS THE #1 COVERED PCSK9 INHIBITOR^{1,†,‡}

Now, more than 80% of prescriptions for Repatha[®] patients cost less than \$50 per month^{2,§}

 **Commercially eligible patients may pay \$5 with the Repatha[®] Copay Card^{**}**

 **Medicare² 72%**
of Repatha[®] prescriptions cost less than \$50^{††}

 **Medicaid² 100%**
of Repatha[®] prescriptions cost less than \$50

Commercial Coverage Status[†]

National Health Plans	Repatha [®] on Formulary
OptumRx [®]	✓
Express Scripts [®] PBM (exclusive as of 1/1/2021)	✓
UnitedHealth Group [®]	✓
Anthem [®]	✓

Medicare Coverage Status[†]

72% of Medicare Part D prescriptions for Repatha[®] patients cost less than \$50 per month²

National Part D Health Plans	Average Out-of-Pocket for Patients ³	Repatha [®]
UnitedHealth Group [®]	\$51.00	✓
Humana [®]	\$51.00	✓
Express Scripts [®] PBM	\$37.00	✓
Anthem [®]	\$45.00	✓

For additional support on coverage, call the **Virtual RAS** number **1-844-889-9222** or visit [RepathaHCP.com](https://www.RepathaHCP.com)

*Includes commercial, health exchange, Medicaid, and Medicare lives. [†]Coverage status does not imply a difference in clinical efficacy, safety or other clinical outcome. [‡]As of December 2020, based on MMIT data. This information is subject to change without notice. For the most up-to-date and complete information regarding the status of Repatha[®], please contact the relevant payer directly. [§]Based on IQVIA claims data from 01/2020 through 12/2020 using commercial, health exchange, Medicare, and Medicaid claims. ^{**}See back for eligibility requirements and terms and conditions for the Repatha[®] Copay Card. ^{††}Patients out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit they are currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.

INDICATIONS

Repatha[®] is indicated:

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha[®] is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha[®]. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha[®].

Please see following page for additional Important Safety Information.

 **Repatha[®]**
(evolocumab) injection
140 mg/mL

Patients may pay \$5 per month

Eligible commercially insured patients **may pay \$5 per month** with the Repatha® Copay Card.**
To learn more or for patient enrollment, visit [Repatha.com/copaycard](https://www.Repatha.com/copaycard)



**Eligibility Requirements and Terms and Conditions for Repatha® Copay Card:

Open to patients with commercial prescription insurance and who are not enrolled in any government-funded program that pays for prescription drugs. This program is not open to uninsured patients or patients enrolled in any federal-, state-, or government-funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE®, or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary insurance coverage under this offer. Other restrictions, including annual copay maximum limits may apply. This offer is subject to change or discontinuation without notice. Please visit Repatha.com for full terms and conditions.

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see Repatha® full [Prescribing Information](#).

References: 1. Data on file, Amgen; [1]; 2021. 2. Data on file, Amgen; [2]; 2021. 3. Data on file, Amgen; [3]; 2021.

